Xencor, Inc. (NASDAQ:XNCR) Given Average Rating of "Moderate Buy" by Analysts

Key Points

• Xencor, Inc. has received a consensus rating of "Moderate Buy" from eleven analysts, with ratings including two sells, one hold, seven buys, and one strong buy.
• The average 12-month price target for Xencor is $24.22, though recent ratings have varied, with Bank of America lowering its target to $12.00.
• Xencor reported a quarterly revenue of $43.61 million, significantly exceeding analyst estimates, and improved its earnings per share to ($0.41), beating expectations by $0.37.

Shares of Xencor, Inc. (NASDAQ:XNCR - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the eleven analysts that are currently covering the company, MarketBeat.com reports. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $24.2222.

XNCR has been the subject of a number of recent analyst reports. Cantor Fitzgerald raised shares of Xencor to a "strong-buy" rating in a research report on Wednesday. Weiss Ratings reissued a "sell (e+)" rating on shares of Xencor in a research report on Saturday, September 27th. Bank of America downgraded shares of Xencor from a "buy" rating to a "neutral" rating and decreased their price objective for the stock from $23.00 to $12.00 in a report on Wednesday, September 3rd. Wedbush reaffirmed an "outperform" rating and issued a $26.00 price objective on shares of Xencor in a report on Tuesday, September 2nd. Finally, Barclays began coverage on shares of Xencor in a report on Wednesday, September 17th. They issued an "underweight" rating and a $6.00 price objective for the company.

Institutional Investors Weigh In On Xencor

A number of hedge funds and other institutional investors have recently modified their holdings of XNCR. Principal Financial Group Inc. grew its holdings in shares of Xencor by 2.5% during the first quarter. Principal Financial Group Inc. now owns 348,726 shares of the biopharmaceutical company's stock worth $3,710,000 after purchasing an additional 8,581 shares during the last quarter. Invesco Ltd. lifted its stake in shares of Xencor by 44.3% during the first quarter. Invesco Ltd. now owns 656,201 shares of the biopharmaceutical company's stock valued at $6,982,000 after acquiring an additional 201,456 shares during the period. Goldman Sachs Group Inc. lifted its stake in shares of Xencor by 89.9% during the first quarter. Goldman Sachs Group Inc. now owns 726,734 shares of the biopharmaceutical company's stock valued at $7,732,000 after acquiring an additional 344,088 shares during the period. Cubist Systematic Strategies LLC acquired a new position in shares of Xencor during the first quarter valued at $1,655,000. Finally, US Bancorp DE lifted its stake in shares of Xencor by 312.0% during the first quarter. US Bancorp DE now owns 10,432 shares of the biopharmaceutical company's stock valued at $111,000 after acquiring an additional 7,900 shares during the period.

Xencor Stock Performance

NASDAQ XNCR opened at $13.03 on Friday. Xencor has a one year low of $6.92 and a one year high of $27.24. The company's 50 day moving average price is $9.19 and its 200 day moving average price is $9.05. The firm has a market capitalization of $929.30 million, a price-to-earnings ratio of -5.43 and a beta of 0.96.

Xencor (NASDAQ:XNCR - Get Free Report) last posted its quarterly earnings data on Wednesday, August 6th. The biopharmaceutical company reported ($0.41) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.78) by $0.37. The company had revenue of $43.61 million for the quarter, compared to analyst estimates of $22.59 million. Xencor had a negative net margin of 121.52% and a negative return on equity of 25.75%. The business's quarterly revenue was up 82.4% on a year-over-year basis. During the same quarter last year, the firm posted ($1.07) earnings per share. Sell-side analysts forecast that Xencor will post -3.68 EPS for the current fiscal year.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.